RACHEL BROWN: Open Payments
NPI 1750940375 · OKEMOS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 11 payments from 9 companies in 2025. Trend: 2023 $641 · 2024 $574 · 2025 $736
Food & beverage: $736
| Company | Payments | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | 2 | $194 |
| Alnylam Pharmaceuticals Inc. | 1 | $120 |
| TG Therapeutics, Inc. | 1 | $107 |
| ARGENX US, INC. | 1 | $104 |
| Janssen Biotech, Inc. | 1 | $81 |
| Genentech USA, Inc. | 2 | $55 |
| Amgen Inc. | 1 | $30 |
| Eisai Inc. | 1 | $24 |
| GENZYME CORPORATION | 1 | $22 |
Products named: ULTOMIRIS, AMVUTTRA, BRIUMVI, VYVGART, TREMFYA, Ocrevus Zunovo, Xolair, Leqembi.
Industry payments across MI — which companies pay providers there.
